Introduction: Rethinking the Therapeutic Window in Acute Ischemic Stroke

For several decades, emergency physicians and neurologists strictly adhered to a rigid 4.5-hour time limit for intravenous reperfusion therapy in acute ischemic stroke. Consequently, clinicians routinely excluded late-arriving patients, wake-up stroke presentations, and individuals with unknown time of symptom onset from receiving effective thrombolytic therapy. However, modern neuroimaging tools have fundamentally transformed this restrictive paradigm by shifting clinical focus from a strict time clock to individual tissue viability. Emerging clinical trials show that significant salvageable penumbral tissue often persists long after the traditional window closes. Therefore, implementing extended window IV thrombolysis offers new therapeutic options for carefully selected stroke patients presenting between 4.5 and 24 hours from last known well. A comprehensive systematic review and meta-analysis published in Neurology evaluates the efficacy, safety, and between-study heterogeneity of this expanded approach across randomized clinical trials. By pooling data from thousands of patients, researchers provide crucial evidence regarding functional recovery, mortality, and intracranial hemorrhage risks. Moreover, these findings offer clear guidance for acute care clinicians seeking to optimize emergency protocol decisions and improve long-term functional recovery for patients. As stroke remains a major cause of adult disability globally, expanding safe eligibility criteria represents a pivotal advance in neurovascular emergency medicine.

Methodology of the Meta-Analysis and Study Selection

To evaluate reperfusion outcomes beyond the standard timeframe, investigators conducted a rigorous systematic review across MEDLINE, Cochrane Library, and ClinicalTrials.gov from inception through February 2026. The search identified eligible randomized controlled trials and individual patient-data meta-analyses comparing intravenous thrombolysis with control care in acute ischemic stroke patients presenting after 4.5 hours. Ultimately, fifteen studies representing eighteen randomized controlled trials and encompassing 5,168 total patients met all inclusion criteria for the primary analysis. Furthermore, the researchers examined specific patient selection strategies across the enrolled clinical trials. Eleven of the eighteen trials required advanced physiological imaging, such as computed tomography perfusion or magnetic resonance perfusion mismatch, or diffusion-weighted imaging with fluid-attenuated inversion recovery mismatch, to confirm salvageable penumbral tissue. Conversely, seven trials permitted noncontrast computed tomography or computed tomography angiography to guide treatment allocation. The primary outcome was excellent functional recovery, defined as a modified Rankin Scale score of 0 or 1 at 90 days post-stroke. Additionally, secondary efficacy endpoints included overall functional independence, defined as a modified Rankin Scale score of 0 to 2, and ordinal disability shifts across all strata. Safety endpoints included 90-day all-cause mortality and symptomatic intracranial hemorrhage occurrence.

Efficacy Outcomes: Excellent Functional Recovery and Reduced Disability

The pooled findings demonstrated statistically significant improvements across all key functional recovery metrics for patients receiving late-window thrombolysis. Specifically, intravenous thrombolysis significantly increased the proportion of patients achieving an excellent functional outcome at 90 days compared with control therapy. Excellent recovery occurred in 40.3% of patients in the thrombolysis arm versus 33.2% in the control group. This improvement corresponds to a pooled risk ratio of 1.21 with a 95% confidence interval of 1.13 to 1.30. Consequently, the number needed to treat to achieve one additional excellent functional outcome was calculated at 14. Furthermore, secondary efficacy analyses confirmed broader neurological benefits across the full spectrum of post-stroke disability. Thrombolytic therapy significantly boosted the rate of overall functional independence at three months. Moreover, the ordinal shifts across modified Rankin Scale score strata demonstrated a higher likelihood of lower global disability levels. These positive outcomes remained consistent despite variations in baseline stroke severity and time of presentation. Therefore, the meta-analysis confirms that reperfusion therapy delivers robust therapeutic benefit when salvageable brain tissue is present, successfully challenging the traditional assumption that thrombolytic efficacy entirely disappears after 4.5 hours.

Evaluating Sources of Between-Study Heterogeneity and Subgroup Drivers

Although the overall primary efficacy results favored thrombolytic intervention, clinical trials in this domain exhibited noteworthy heterogeneity in design and patient selection. To address these variations, the study authors executed multivariable meta-regression modeling. This statistical approach simultaneously evaluated thrombolytic agents, endovascular thrombectomy background context, vascular territory, and imaging selection modalities to disentangle confounded outcome predictors. Importantly, the analysis compared different thrombolytic agents, specifically alteplase and tenecteplase, within extended window IV thrombolysis protocols. Both agents demonstrated significant functional benefit, although tenecteplase displayed practical advantages in administration simplicity and rapid clot dissolution. Additionally, the presence of concurrent large vessel occlusion and subsequent endovascular thrombectomy altered treatment dynamics. Patients receiving combined bridging thrombolysis and thrombectomy maintained favorable recovery patterns without compromising endovascular procedure safety. Furthermore, imaging selection strategy served as a key modifier of treatment heterogeneity. Trials utilizing advanced perfusion mismatch selection consistently identified candidates with large penumbral zones and small core infarcts. Consequently, these physiological criteria yielded clearer clinical benefits compared to trials relying solely on noncontrast imaging. These insights emphasize that careful imaging selection effectively mitigates heterogeneity in clinical practice.

Safety Profile and Risk-Benefit Dynamics of extended window IV thrombolysis

Evaluating safety outcomes remains essential when clinicians consider expanding thrombolytic indications beyond established standard timeframes. The meta-analysis systematically evaluated primary safety parameters, including symptomatic intracranial hemorrhage and 90-day all-cause mortality. As anticipated with thrombolytic agents, intravenous thrombolysis in the extended window was associated with a higher risk of symptomatic intracranial hemorrhage compared to control treatment. However, despite this elevated bleeding incidence, overall 90-day mortality rates did not significantly differ between the thrombolysis and control cohorts. This critical safety finding indicates that the increased risk of hemorrhagic transformation does not offset the substantial functional benefits gained from early penumbral reperfusion. Furthermore, advanced neuroimaging selection helped mitigate severe hemorrhagic complications by excluding patients with large established core infarcts. When clinicians screen candidates effectively using tissue viability criteria, the net clinical benefit strongly favors intervention. Therefore, the overall risk-benefit balance supports offering thrombolysis to eligible late-arriving patients, provided clinicians adhere to strict imaging protocols. These results provide vital reassurance to emergency medical teams, neurologists, and neurointensivists managing complex stroke cases under urgent time constraints.

Clinical Implications for Emergency and Stroke Care

The findings of this comprehensive meta-analysis carry major practical implications for emergency departments, neurointensive care units, and stroke centers worldwide. Historically, many healthcare systems excluded late-presenting stroke patients due to strict time-based guidelines. However, adopting tissue-based selection strategies allows clinicians to safely extend thrombolytic therapy up to 24 hours from last known well. In acute care settings, establishing rapid access to computed tomography perfusion or magnetic resonance imaging is vital for identifying viable ischemic penumbra. Furthermore, emergency protocols must integrate streamlined triage workflows so that imaging interpretation and drug administration occur without unnecessary delays. In resource-constrained environments, utilizing noncontrast computed tomography with computed tomography angiography may also offer a pragmatic approach when advanced perfusion technology is unavailable. Additionally, training multidisciplinary emergency teams on tenecteplase dosing and patient selection can improve delivery speed and clinical outcomes. Ultimately, moving away from rigid time cutoffs toward individualized physiological assessment ensures that more stroke survivors regain functional independence. As clinical guidelines continue to evolve globally, extended window IV thrombolysis will likely become a routine standard of care in modern emergency stroke management.

What is extended window IV thrombolysis for acute ischemic stroke?

Extended window IV thrombolysis refers to administering intravenous clot-dissolving medications to acute ischemic stroke patients between 4.5 and 24 hours after symptom onset or last known well. Rather than relying solely on strict time cutoffs, clinicians use advanced neuroimaging to identify salvageable brain tissue before initiating reperfusion therapy.

How does imaging selection guide extended window thrombolysis?

Advanced imaging, such as computed tomography perfusion or magnetic resonance perfusion mismatch, distinguishes non-viable ischemic core from salvageable penumbra. By selecting patients who possess a small core and substantial hypoperfused penumbral tissue, clinicians can identify individuals who will safely benefit from late thrombolysis despite arriving past 4.5 hours.

Does late thrombolysis increase the risk of mortality or intracranial hemorrhage?

While extended window thrombolysis increases the risk of symptomatic intracranial hemorrhage compared to non-thrombolysed controls, meta-analyses show no significant increase in overall 90-day mortality. The substantial gain in 90-day functional independence and reduced disability outweighs the elevated bleeding risk in carefully screened patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Healthcare professionals should evaluate clinical decisions based on individual patient parameters and local protocols. Refer to the latest local and national guidelines for clinical practice.

References

1. Doheim MF et al. Exploring Between-Study Heterogeneity in Extended-Window IV Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis of 18 Randomized Controlled Trials. Neurology. 2026 Aug 11. doi: 10.1212/WNL.0000000000218331. PMID: 42475651.


2. Palaiodimou L et al. IV Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Neurology. 2026 Jul 23. doi: 10.1212/WNL.0000000000218294. PMID: 42492020.


3. Campbell BCV et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394(10193):139-147.